INTRODUCTION: Reliable information on stem cell toxicity and mobilization of stem cells for autologous stem cell transplantation (SCT) after induction treatment with a combination of bendamustine, prednisone and bortezomib (BPV) is missing. MATERIALS AND METHODS: A retrospective analysis of peripheral blood stem cell mobilization and autologous SCT was performed in 35 patients with MM who had received at least one cycle of a BPV-induction therapy consisting of bendamustine 60 mg/m(2) on days 1 and 2, bortezomib 1.3 mg/m(2) on days 1, 4, 8 and 11 and prednisone 100 mg on days 1, 2, 4, 8 and 11 between October 2008 and May 2014. The mobilization regimen consisted of cyclophosphamide 4 g/m(2) and G-CSF (2 × 5 μg/kg). Apheresis was started as soon as peripheral CD34(+) counts exceeded 20 × 10(6)/L with a harvest target of 8 × 10(6) CD34(+)/kg. The minimal accepted target was 2 × 10(6) CD34(+)/kg. The transplantation conditioning therapy consisted of melphalan 200 mg/m(2). RESULTS: A median number of two (range 1-5) BPV cycles were given. The majority of patients (n = 31, 89 %) responded with two sCR, five nCR, 11 VGPR and 13 PR after BPV induction. Three patients had MR, and one SD. Stem cell mobilization and harvest were successful in all patients. In 19 of 35 patients (54 %), a single apheresis was sufficient to reach the target. The median number of aphereses was one (range 1-4), and the median CD34(+) cell-count/kg was 13.5 (range 3.2-33.1) × 106. All patients received an autologous SCT. Engraftment was successful in 34 of 35 patients. The median time to a leukocyte count >l × 10(9)/L was 11 days, and the time to untransfused platelet count of >50 × 10(9)/L was 13 days. Thirty-four patients (97 %) responded after the autologous SCT with 11 sCR, two CR, seven nCR, seven VGPR and seven PR. The progression-free survival at 18 months was 87 %, and overall survival was 92 %. CONCLUSION: Stem cell mobilization and autologous SCT are feasible in MM patients who have received BPV-induction therapy .
INTRODUCTION: Reliable information on stem cell toxicity and mobilization of stem cells for autologous stem cell transplantation (SCT) after induction treatment with a combination of bendamustine, prednisone and bortezomib (BPV) is missing. MATERIALS AND METHODS: A retrospective analysis of peripheral blood stem cell mobilization and autologous SCT was performed in 35 patients with MM who had received at least one cycle of a BPV-induction therapy consisting of bendamustine 60 mg/m(2) on days 1 and 2, bortezomib 1.3 mg/m(2) on days 1, 4, 8 and 11 and prednisone 100 mg on days 1, 2, 4, 8 and 11 between October 2008 and May 2014. The mobilization regimen consisted of cyclophosphamide 4 g/m(2) and G-CSF (2 × 5 μg/kg). Apheresis was started as soon as peripheral CD34(+) counts exceeded 20 × 10(6)/L with a harvest target of 8 × 10(6) CD34(+)/kg. The minimal accepted target was 2 × 10(6) CD34(+)/kg. The transplantation conditioning therapy consisted of melphalan 200 mg/m(2). RESULTS: A median number of two (range 1-5) BPV cycles were given. The majority of patients (n = 31, 89 %) responded with two sCR, five nCR, 11 VGPR and 13 PR after BPV induction. Three patients had MR, and one SD. Stem cell mobilization and harvest were successful in all patients. In 19 of 35 patients (54 %), a single apheresis was sufficient to reach the target. The median number of aphereses was one (range 1-4), and the median CD34(+) cell-count/kg was 13.5 (range 3.2-33.1) × 106. All patients received an autologous SCT. Engraftment was successful in 34 of 35 patients. The median time to a leukocyte count >l × 10(9)/L was 11 days, and the time to untransfused platelet count of >50 × 10(9)/L was 13 days. Thirty-four patients (97 %) responded after the autologous SCT with 11 sCR, two CR, seven nCR, seven VGPR and seven PR. The progression-free survival at 18 months was 87 %, and overall survival was 92 %. CONCLUSION: Stem cell mobilization and autologous SCT are feasible in MMpatients who have received BPV-induction therapy .
Authors: Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila El Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Edo Vellenga; Annemiek Broyl; Igor W Blau; Katja C Weisel; Shulamiet Wittebol; Gerard M J Bos; Marian Stevens-Kroef; Christof Scheid; Michael Pfreundschuh; Dirk Hose; Anna Jauch; Helgi van der Velde; Reinier Raymakers; Martijn R Schaafsma; Marie-Jose Kersten; Marinus van Marwijk-Kooy; Ulrich Duehrsen; Walter Lindemann; Pierre W Wijermans; Henk M Lokhorst; Hartmut M Goldschmidt Journal: J Clin Oncol Date: 2012-07-16 Impact factor: 44.544
Authors: James R Berenson; Ori Yellin; Alberto Bessudo; Ralph V Boccia; Stephen J Noga; Donald S Gravenor; Dipti Patel-Donnelly; Robert S Siegel; Tarun Kewalramani; Edward J Gorak; Youram Nassir; Regina A Swift; Debra Mayo Journal: Br J Haematol Date: 2012-11-15 Impact factor: 6.998
Authors: Pieter Sonneveld; Hartmut Goldschmidt; Laura Rosiñol; Joan Bladé; Juan José Lahuerta; Michele Cavo; Paola Tacchetti; Elena Zamagni; Michel Attal; Henk M Lokhorst; Avinash Desai; Andrew Cakana; Kevin Liu; Helgi van de Velde; Dixie-Lee Esseltine; Philippe Moreau Journal: J Clin Oncol Date: 2013-07-29 Impact factor: 44.544
Authors: Wolfram Pönisch; Malvina Bourgeois; Barbara Moll; Simone Heyn; Nadja Jäkel; Ina Wagner; Robert Rohrberg; Hans-Jürgen Hurtz; Marion Schmalfeld; Michael Aßmann; Thomas Edelmann; Martin Mohren; Franz Albert Hoffmann; Cornelia Becker; Andreas Schwarzer; Uta Schönfelder; Thomas Zehrfeld; Gerald Hensel; Kerstin Löschcke; Rainer Krahl; Haifa Al Ali; Dietger Niederwieser Journal: J Cancer Res Clin Oncol Date: 2012-11-25 Impact factor: 4.553
Authors: Juliane Beck; Andreas Schwarzer; Dietrich Gläser; Lars-Olof Mügge; Jens Uhlig; Simone Heyn; Brigitte Kragl; Martin Mohren; Franz Albert Hoffmann; Thoralf Lange; Thomas Schliwa; Thomas Zehrfeld; Cornelia Becker; Ute Kreibich; Cornelia Winkelmann; Thomas Edelmann; Marc Andrea; Marius Bill; Madlen Jentzsch; Sebastian Schwind; Dietger Niederwieser; Wolfram Pönisch Journal: J Cancer Res Clin Oncol Date: 2017-08-21 Impact factor: 4.553
Authors: Tanja Holzhey; Wolfram Pönisch; Song-Yau Wang; Madlen Holzvogt; Bruno Holzvogt; Marc Andrea; Thomas Zehrfeld; Doreen Hammerschmidt; Franz Albert Hoffmann; Cornelia Becker; Andreas Schwarzer; Maik Schwarz; Uta Schönfelder-Fricke; Thomas Edelmann; Leanthe Braunert; Georg-Nikolaus Franke; Madlen Jentzsch; Sebastian Schwind; Markus Bill; Juliane Grimm; Yvonne Remane; Uwe Platzbecker; Markus Scholz Journal: J Cancer Res Clin Oncol Date: 2021-01-12 Impact factor: 4.553
Authors: Sandro M Wagner; Thomas Melchardt; Alexander Egle; Teresa Magnes; Cathrin Skrabs; Philipp Staber; Ingrid Simonitsch-Klupp; Michael Panny; Barbara Lehner; Richard Greil; Felix Keil; Ulrich Jäger; Christian Sillaber Journal: Eur J Haematol Date: 2020-01-10 Impact factor: 2.997